The Pathogenic Potential of a Microbe

Arturo Casadevall
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

ABSTRACT
Virulence is a microbial property that is realized only in susceptible hosts. There is no absolute measurement for virulence, and consequently it is always measured relative to a standard, usually another microbe or host. This article introduces the concept of pathogenic potential, which provides a new approach to measuring the capacity of microbes for virulence. The pathogenic potential is proportional to the fraction of individuals who become symptomatic after infection with a defined inoculum and can include such attributes as mortality, communicability, and the time from infection to disease. The calculation of the pathogenic potential has significant advantages over the use of the lethal dose that kills 50% of infected individuals (LD_{50}) and allows direct comparisons between individual microbes. An analysis of the pathogenic potential of several microbes for mice reveals a continuum, which in turn supports the view that there is no dividing line between pathogenic and nonpathogenic microbes.

KEYWORDS
formula, pathogenesis, virulence

The germ theory of disease posited that certain microbes caused specific diseases (e.g., *Mycobacterium tuberculosis* caused tuberculosis). Furthermore, it was rapidly apparent that there were differences in virulence within a microbial species (1). Virulence is the relative capacity of a microbe to cause damage, with the term “relative” being a necessary component of the definition since there are no absolute measures of virulence (2). Virulence is always measured relative to a standard, such as another microbe or host. Today, most comparisons of virulence are done within a microbial species, with investigators comparing the virulence of the wild type to that of an experimentally modified strain, such as one with a gene deletion or mutation. Virulence is expressed only in a susceptible host, and its measurement is critically dependent on the host system used (3).

Historically, the measurement of virulence has relied on some quantifiable outcome on the host, such as mortality. The most commonly used measurement of virulence is the lethal dose required to kill 50% of infected hosts, referred to as the LD_{50}. The LD_{50} measurement has the advantage that it allows comparisons across microbes, and the use of host death provides a nonequivocal endpoint. However, the LD_{50} has the considerable limitation that it is a coarse measure that is not applicable to those host-microbe interactions where host death does not occur or is a very rare outcome. Another limitation of the LD_{50} is that it is focused on mortality and thus misses other outcomes of infection, such as chronicity and latency. However, perhaps the greatest limitation of LD_{50} studies is lack of discriminatory power such that 10-fold differences in the size of the inoculum can lead to the same LD_{50} value (for an example, see reference 4).

Given the limitations of the LD_{50}, some investigators have developed approaches for measuring virulence that are not dependent on mortality. Beynen et al. developed a symptomatic assessment scale that relied on measuring a variety of parameters in mice with gallstones (5). Soothill et al. used hypothermia as a reliable early indicator of mortality in mice and developed the HID_{50} or 50% hypothermia-inducing dose (6).
These formulations, like the LD$_{50}$, are useful for the specific situations for which they were developed but lack global applicability for comparison across microbes and potential hosts.

**The pathogenic potential of a microbe.** The goal of this effort was to find a mathematical relationship that allows a quantitative measure of the capacity of a certain microbe for pathogenicity. To accomplish this, I propose the concept of the pathogenic potential (PP). In this phraseology, the word “pathogenic” retains the meaning proposed earlier (2) as the capacity of a microbe to cause damage in a host and the word “potential” acknowledges that no microbe can be pathogenic in the absence of a host. In considering the factors that contributed to the pathogenic potential, it was important to account for the fact that the damage incurred by a host during a host-microbe interaction was variable. Clinical symptoms manifest themselves only when the host-microbe interaction results in sufficient host damage to disrupt homeostasis, and death ensues when the damage is so overwhelming that it precludes repair and a return to homeostasis.

The pathogenic potential (PP) of a microbe is proposed to be proportional to the ratio of the fraction symptomatic (Fs) and the infecting inoculum ($I$): $PP \propto \frac{Fs}{I}$.

Since symptomatology can range from a passing malaise to death, this formulation does not capture the severe impact of host-microbe interactions associated with host mortality. To include host-microbe interactions that result in death, the ratio is modified by multiplying it by the 10th power of the mortality fraction: $PP = \frac{(Fs/I)10^M}{1}$. In this formulation, the $Fs/I$ term includes the microbial pathogenicity and host susceptibility factors essential for microbial pathogenesis, while the $10^M$ factor is an amplifier to account for host mortality, an extreme outcome of the host-microbe interaction. The $Fs/I$ term is identical to that used previously in developing a formula for the weapon potential of a microbe (7). As will be illustrated below, when actual calculations are done, the $I$ parameter to be used should be the smallest that produces symptoms/death, since progressively larger inocula associated with symptoms/death for all animals will result in a smaller PP. For the mortality amplification, the 10th power was used to allow for the possibility of host-microbe interactions with no mortality, in which case $M = 0.0$, which reduces $10^M$ to 1.0. For host-microbe interactions with 100% mortality, $M = 1.0$, which contributes 10. For example, a microbe that caused symptoms in 100% ($Fs = 1.0$) of those infected with one microbe ($I = 1.0$) and killed every infected host ($M = 1.0$) would have a PP of 10. On the other hand, for host-microbe interactions where there are no symptoms ($Fs = 0.0$), which de facto implies $M = 0.0$, the PP reduces to 0.0. For host-microbe interactions that produce no symptoms but result in lesions to the host, such as granulomas, one can replace the Fs for the fraction of individuals affected. The proposed PP essentially reduces to the inverse of the infecting inoculum when comparing infections with microbes when all hosts become symptomatic, consistent with the definition of virulence as the inverse of inoculum, which was used in the early days of the germ theory (8).

**Pathogenic potential and communicability (or transmissibility).** The PP formulation proposed above does not include the element of communicability. The reason for this omission was to develop a formulation that could be used to compare the pathogenic potentials of microbes independently of their communicability potential and also allow for the comparison of the effects of microbes on individual hosts independently of their effects on the entire population of susceptible hosts. The relationship between communicability and virulence can be very complex (9), and it is relevant for some pathogenic microbes and not others. For *M. tuberculosis*, the capacity for communicability is dependent on its ability to cause lung damage and consequent dissemination through aerosolization of infective bacteria. However, the virulence of *Bacillus anthracis* is not dependent on communicability, and anthrax is not a transmissible disease. For other microbes, such as BK virus, communicability is common, but disease is extremely rare, unless the host is immune suppressed. Hence, the relationship
between pathogenic potential and communicability is microbe specific, with virulence and communicability being dependent variables for some host-microbe relationships and not others.

The element of communicability is also relevant to have an impact on the host species, where it functions as an amplifier of threat. Given that communicability (C) is an amplifier, it can be added to the pathogenic potential as a multiplier term. Hence, a formulation for PP that includes the contribution of transmissibility (PP_C) can be 

$$PP_C = \frac{FS}{I} (10^M C)$$

Since there are no absolute values for C, it can be assigned a value ranging from 1 (not communicable) to 100 (every case leads to one or more new cases) based on epidemiological data. Separating PP from C allows these properties to be considered separately when comparing the outcome of host-microbe interactions in individuals and populations.

**The element of time.** Neither PP nor PP_C includes time to disease. The element of time is often a central determinant of how the pathogenic potential of a microbial species is perceived. When the words “fulminant” and “aggressive” are used in the context of infectious diseases, they usually connote an element of rapidity or shortness of time between infection and disease. Cryptococcosis, HIV infection, and disseminated anthrax have in common close to 100% mortality in affected individuals if untreated, but these diseases are often viewed differently with respect to their relative virulence because the times to death differ greatly. Diseases that kill a host in a short time after infection create a much greater impression than those where there is a long time interval between infection and demise. For example, anyone who has witnessed a case of meningococcal meningitis and/or sepsis cannot but be impressed with how fulminant that disease can be, which can progress from a mild condition to death in a matter of hours. For those who want to consider the element of time, this can be easily included in either the PP or PP_C formulations by multiplying these calculated parameters by 1/T, where T is time. Consequently, infectious diseases where the times to symptoms are shorter will yield a higher PP or PP_C than those that take a long time from infection to disease.

**The exceptionality of certain toxin-mediated diseases.** Toxin-mediated diseases are different from other infectious diseases in that they can trigger symptoms irrespective of the immune system function (2), and for some diseases, the connection between microbe and host can be both temporally and/or spatially separate. Furthermore, these are a diverse set of diseases for which the PP is applicable to some but not others. For example, the proposed PP formulation works for tetanus, where skin infection with an inoculum of Clostridium tetani results in certain fraction of infected individuals developing tetanus. In contrast, for botulism and staphylococcal food poisoning, the disease results from the ingestion of a preformed toxin whose production is temporally and spatially separate from introduction into the host, and the PP formulation proposed above is not applicable, since there is no relevant inoculum. However, the PP formulation can be modified to substitute the inoculum for the toxin dose ingested to yield PP_D. Hence, for toxin-mediated diseases where the toxin in produced within the host as a consequence of infection, the PP applies, while PP_D can be used for microbial diseases resulting from the ingestion or inoculation of preformed toxin. Like PP, the PP_D can be modified to take into account the element of time but when these diseases are not communicable and C can be assigned the value of 1.0.

**Calculations using the pathogenic potential formulation.** Using the PP formulation with experimental data demonstrates advantages as well as some caveats in its application. The first example will use published data on the virulence of Salmonella enterica serovar Typhimurium strains differing in lipopolysaccharide side chains (4). Table 1 lists the original data found in Table 2 of reference 4 and the calculated PP. One immediate advantage is that the PP calculation remains useful for making comparisons between strains when there is difference between the assumed inocula and the actual
inocula as revealed by postinfection plating or plaque assays. Another advantage is that the PP calculation discriminates between conditions where 10-fold differences in inoculum yielded the same LD_{50}. For example, for strain 2201, there is 50% mortality with bacterial inocula of both 10^5 and 10^4 producing identical LD_{50} values, but the PP

### TABLE 1 Analysis of pathogenic potential of *Salmonella enterica* serovar Typhimurium in mice based on mortality data

| Strain          | 5 × 10^2 | 5 × 10^3 | 5 × 10^6 | 5 × 10^7 |
|-----------------|----------|----------|----------|----------|
| 2201            | 1.0      | 1.7 × 10^-7 | 1.7 × 10^-6 | 5.3 × 10^-6 | 5.3 × 10^-5 | 0.0 |
| 2202            | 1.0      | 2.0 × 10^-7 | 1.3 × 10^-6 | 8.0 × 10^-6 | 2.5 × 10^-5 | 0.0 |
| 2203            | 1.0      | 2.5 × 10^-7 | 2.5 × 10^-6 | 2.0 × 10^-5 | 4.0 × 10^-5 | 0.0 |
| 2204            | 0.8      | 1.3 × 10^-7 | 1.0 × 10^-6 | 2.5 × 10^-6 | 0.0       | 0.0 |
| 2205            | 0.8      | 1.3 × 10^-7 | 6.3 × 10^-7 | 3.2 × 10^-6 | 3.2 × 10^-5 | 0.0 |
| 2206            | 1.0      | 2.0 × 10^-7 | 1.6 × 10^-6 | 3.2 × 10^-6 | 0.0       | 0.0 |

*a* Enterococcus faecalis

| Strain          | 0.5 | 1.0 | 2.0 | 6.0 | 5.0 | 1.1 | 2.9 | 6.3 | 4.7 |
|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| *Haemophilus influenzae* | 0.5 | 1.0 | 1.0 | 4.7 | 1.0 | 1.0 | 1.0 | 3.2 | 1.6 |
| *Staphylococcus aureus* | 0.5 | 2.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |

### TABLE 2 Pathogenic potential calculations for several microbes in mice

| Microbe or condition             | Mortality   | Inoculum | PP   | Reference |
|----------------------------------|-------------|----------|------|-----------|
| Theoretical maximum              | 1.0         | 1.0 × 10^6 | 1.0 × 10^1 | This work |
| *Francisella tularensis*         | 0.5         | 2.0 × 10^6 | 1.6 × 10^6 | 13       |
| *Bacillus anthracis*             | 0.5         | 2.6 × 10^6 | 1.2 × 10^6 | 14       |
| *Brucella suis*                  | 0.5         | 3.8 × 10^6 | 8.3 × 10^-1 | 15       |
| *Toxoplasma gondii*              | 0.5         | 1.5 × 10^6 | 2.1 × 10^-1 | 16       |
| *Coccidioides immitis*           | 0.5         | 1.7 × 10^6 | 1.9 × 10^-1 | 17       |
| *Klebsiella pneumoniae*          | 0.5         | 1.9 × 10^6 | 1.7 × 10^-1 | 18       |
| *Streptococcus pneumoniae*       | 0.5         | 3.0 × 10^6 | 1.1 × 10^-1 | 19       |
| *Yersinia pestis*                | 0.5         | 3.7 × 10^6 | 8.5 × 10^-2 | 20       |
| *Cryptococcus neoformans*        | 0.5         | 5.1 × 10^6 | 6.2 × 10^-2 | 21       |
| *Vibrio vulnificus*              | 0.5         | 7.5 × 10^6 | 4.2 × 10^-2 | 22       |
| *Herpes simplex virus*           | 0.5         | 2.2 × 10^6 | 1.4 × 10^-2 | 23       |
| *Escherichia coli*               | 0.5         | 1.0 × 10^6 | 3.2 × 10^-3 | 24       |
| *Candida albicans*               | 0.5         | 6.6 × 10^6 | 4.8 × 10^-4 | 25       |
| *Murine cytomegalovirus*         | 0.5         | 5.0 × 10^6 | 6.3 × 10^-5 | 26       |
| *Aspergillus fumigatus*          | 0.25        | 6.0 × 10^6 | 3.0 × 10^-5 | 27       |
| *Group B streptococcus*          | 0.5         | 6.3 × 10^6 | 5.0 × 10^-5 | 28       |
| *Murine adenovirus*              | 0.5         | 1.0 × 10^6 | 3.2 × 10^-5 | 29       |
| *Listeria monocytogenes*         | 0.5         | 2.4 × 10^6 | 1.3 × 10^-5 | 30       |
| *Nocardia asteroides*            | 0.5         | 8.5 × 10^6 | 3.7 × 10^-6 | 31       |
| *Shigella sonnei*                | 0.5         | 1.6 × 10^6 | 2.0 × 10^-6 | 32       |
| *Naegleria fowleri*              | 0.75        | 5.0 × 10^6 | 3.2 × 10^-6 | 33       |
| *Bacillus cereus*                | 0.5         | 1.0 × 10^6 | 3.2 × 10^-7 | 34       |
| *Staphylococcus saprophyticus*   | 0.5         | 2.7 × 10^6 | 1.2 × 10^-7 | 35       |
| *Bacillus thuringiensis*         | 0.5         | 1.1 × 10^6 | 2.9 × 10^-7 | 36       |
| *Pseudomonas aeruginosa*         | 0.5         | 5.0 × 10^6 | 6.3 × 10^-8 | 37       |
| *Legionella pneumophila*         | 0.5         | 6.7 × 10^6 | 4.7 × 10^-8 | 38       |
| *Staphylococcus epidermidis*     | 0.5         | 6.0 × 10^6 | 5.3 × 10^-8 | 39       |
| *Staphylococcus aureus*          | 0.5         | 1.0 × 10^6 | 3.2 × 10^-8 | 40       |
| *Haemophilus influenzae* type B +| 0.5         | 2.0 × 10^6 | 1.6 × 10^-8 | 41       |
| *mucin*                          | 0.5         | 3.4 × 10^6 | 9.3 × 10^-8 | 42       |
| *Enterococcus faecalis*          | 0.5         | 2.6 × 10^6 | 1.2 × 10^-8 | 43       |

*The* PP calculation used literature information on the mortality of mice infected with these microbes. For the calculation, Fs was assumed to 1.0 in all instances, which means that the PP reduces to the inverse of the inoculum modified by the mortality parameter. In those studies where there were multiple microbial strains and different mouse strains, the values used are those that had the largest effects. The PP calculations in this table are for illustrative purposes only, and the reader is cautioned that the studies listed above used different mouse strains and infection routes. Hence, comparisons among the listed microbes should be done cautiously, and the major goal of this listing is to show that these lie on a continuum with regard to their pathogenicity for mice.

*Mixing* the inoculum with mucin reduces the dose needed to cause mortality as the mucin presumably interferes with host defense mechanisms.
TABLE 3 The pathogenic potential of a microbe varies with the genetic background of the mouse strain*a

| Microbe   | Mouse strain | Mortality | Inoculum | PP   | Reference |
|-----------|--------------|-----------|----------|------|-----------|
| *L. monocytogenes* | C57BL/6    | 0.5       | $9.0 \times 10^5$ | $3.5 \times 10^{-6}$ | 39 |
|            | B10.D2      | 0.5       | $2.2 \times 10^5$ | $1.4 \times 10^{-5}$ | 39 |
|            | B10.A       | 0.5       | $2.2 \times 10^5$ | $1.4 \times 10^{-5}$ | 39 |
|            | BALB/c      | 0.5       | $3.9 \times 10^3$ | $8.1 \times 10^{-3}$ | 39 |
|            | CBA         | 0.5       | $5.0 \times 10^2$ | $6.3 \times 10^{-3}$ | 39 |
|            | A/WySn      | 0.5       | $8.0 \times 10^3$ | $4.0 \times 10^{-4}$ | 39 |
|            | (C57BL/6 × BALB/c)F1 | 0.5       | $3.4 \times 10^4$ | $9.3 \times 10^{-5}$ | 39 |
| *B. anthracis* | A/J         | 0.5       | $2.6 \times 10^0$ | $1.2 \times 10^0$ | 40 |
|            | C3H/HeJ     | 0.5       | $5.6 \times 10^0$ | $5.6 \times 10^{-1}$ | 40 |
|            | BALB/cJ     | 0.5       | $6.6 \times 10^0$ | $4.8 \times 10^{-1}$ | 40 |
|            | C58J        | 0.5       | $9.0 \times 10^0$ | $3.5 \times 10^{-1}$ | 40 |
|            | C57BL/6J    | 0.5       | $1.4 \times 10^1$ | $2.3 \times 10^{-1}$ | 40 |
|            | C57L/J      | 0.5       | $2.2 \times 10^1$ | $1.4 \times 10^{-1}$ | 40 |
| Sendai virus | 129/ReJ 1   | 0.5       | $3.2 \times 10^0$ | $9.9 \times 10^{-1}$ | 41 |
|            | SWR/J       | 0.5       | $5.0 \times 10^2$ | $6.3 \times 10^{-3}$ | 41 |
|            | C58/J       | 0.5       | $1.5 \times 10^3$ | $2.1 \times 10^{-3}$ | 41 |
|            | C57BL/6J    | 0.5       | $2.5 \times 10^4$ | $1.3 \times 10^{-4}$ | 41 |
|            | SJL/J       | 0.5       | $1.0 \times 10^5$ | $3.2 \times 10^{-5}$ | 41 |
| *C. immitis* | BALB/cAnN   | 0.5       | $4.6 \times 10^1$ | $6.9 \times 10^{-2}$ | 17 |
|            | C57BL/10N   | 0.5       | $5.9 \times 10^2$ | $5.4 \times 10^{-3}$ | 17 |
|            | C57BL/6N    | 0.5       | $6.8 \times 10^2$ | $4.7 \times 10^{-3}$ | 17 |
|            | DBA/2NK1    | 0.5       | $1.8 \times 10^5$ | $1.8 \times 10^{-5}$ | 17 |

*aThe PP calculation used literature information for the mortality of mice infected with these microbes. For the PP calculation, Fs was assumed to be 1.0 in all instances, which means that the PP reduces to the inverse of the inoculum modified by the mortality parameter. The PP calculations in this table are for illustrative purposes only, and the reader is cautioned that the studies listed above used different infection conditions. Hence, comparisons among the listed microbes should be done cautiously, and the major goal of the listing in this table is to show that how the changing the host can change the PP.

shows a 10-fold difference between these conditions because it includes the inoculum in the denominator. Furthermore, the calculation of PP allows much finer discrimination for virulence differences than is apparent in simple inoculum versus mortality comparisons. In this regard, it is clear that when comparing strains, the PP can differ depending on the inoculum. For example, strain 2201 appears to be most virulent at the lowest inoculum that causes any mortality, but comparison of the calculated PP of this strain and that of strain 2203 reveals the latter to have a greater PP with the larger inocula.

On the other hand, the inclusion of the Fs term in the PP formulation results in major caveats that must be taken into account to avoid calculation foibles. In calculating the PP for mice, the first issue encountered is that in a mortality study, the Fs is not known, and even if the experimenters had set out to measure this parameter, it is difficult to detect minor symptoms in mice. Hence, for inocula where some mice died, in the sample calculations shown in Table 1 the Fs was set at 1.0 based on the assumption that if the experimental infection was sufficient to kill some mice, then there was a high likelihood that some symptoms were experienced by all survivors. However, setting Fs = 1 clearly does not work when the inoculum is too low to result in any deaths since that would have the effect of producing a very high PP even if all the mice were only transiently ill. Hence, when using the PP formulation, one must be to be careful to consider the type of symptoms measured and to use judgment on the input values.

Implications for microbial pathogenesis. The PPs of several microbes for mice were calculated using information from the literature (Table 2). The listing of the PP for these microbes reveals a continuum in the ability of microbes to disease in mice (Table 2), and it can vary depending on mouse genetics (Table 3). This in turn argues against a fundamental qualitative difference between so-called “pathogenic” and “nonpathogenic” microbes, since one can always increase the inoculum to create...
conditions under which some fraction of infected hosts are symptomatic. Thus, sapro-
ophytic microbes and those that exist in a commensal state in an immunocompetent
host can cause disease if the inoculum is high enough. This was demonstrated in a
famous self-experiment when an investigator ingested $10^{12}$ CFU of *Candida albicans*
and developed a transient illness with fever, shivering, and severe headache that was
accompanied by the presence of yeast in blood and urine, indicating rapid dissemina-
tion from the intestine (10). Consequently, classifications of microbes into pathogenic
and nonpathogenic sets can be futile exercises since such categorizations apply only for
defined inocula in certain hosts. On the other hand, microbes can be stratified accord-
ing to their pathogenic potential, provided that information is available on the Fs per
a given inoculum. Incidentally, the PP formulation is applicable in those situations
where the microbe in question changes its relationship with a host from commensal to
disease, as a result of a change in the host. Continuing with the example of *C. albicans*,
this microbe exists in a commensal state in most human hosts, but when these hosts
are given antimicrobial drugs that affect the indigenous microbiota, the fungal burden
can increase tremendously and can lead to disseminated candidiasis. The *C. albicans*
burden in the gut of individuals treated with antimicrobial drugs can reach $10^{10}$/ml, a
number that approaches the ingestion dose of Krause when the entire gut volume is
taken into account (11).

In summary, the proposed formulation for the PP of a microbe takes into account
the contributions of both the host and the microbe to microbial pathogenesis. The
infec tive inoculum is a function of both the intrinsic virulence of a microbe and host
susceptibility. Microorganisms endowed with the capacity to disrupt host defenses
(virulence factors) tend to require smaller inocula to cause disease in nonimmune
hosts. PP provides a new means to rank microbes with regard to their relative
virulence. The continuity in PP implies the absence of a clear defining line between
so-called “pathogens” and “nonpathogens,” which highlights the futility of asking
questions, such as “What is a pathogen?” (12). In that light, the PP calculation
reinforces the suggestion to focus on the outcome of the host-microbe interaction
rather than the participants (12).

ACKNOWLEDGMENTS

A.C. is supported by NIH grants AI033142, AI052733, and HL059842.

REFERENCES

1. Zinsser H. 1914. Infection and resistance, p 1–27. Macmillan Company,
New York, NY.
2. Casadevall A, Pirofski LA. 1999. Host-pathogen interactions: redefining
the basic concepts of virulence and pathogenicity. Infect Immun 67:
3703–3713.
3. Casadevall A, Pirofski L. 2001. Host-pathogen interactions: the attributes
of virulence. J Infect Dis 184:337–344. https://doi.org/10.1086/322044.
4. Valtonen VV. 1970. Mouse virulence of Salmonella strains: the effect
of different smooth-type O side-chains. J Gen Microbiol 64:255–268.
https://doi.org/10.1099/00221287-63-3-255.
5. Beynen AC, Baumans V, Bertens AP, Havenaar R, Hesp AP, Van Zutphen
LF. 1987. Assessment of discomfort in gallstone-bearing mice: a practical
example of the problems encountered in an attempt to recognize
discomfort in laboratory animals. Lab Anim 21:35–42.
6. Soothill JS, Morton DB, Ahmad A. 1992. The HIDS0 (hypothermia-
inducing dose 50): an alternative to the LD50 for measurement of
bacterial virulence. Int J Exp Pathol 73:95–98.
7. Casadevall A, Pirofski LA. 2004. The weapon potential of a microbe.
Trends Microbiol 12:259–263. https://doi.org/10.1016/j.tim.2004.04.007.
8. Zinsser H, Bayne-Jones S. 1939. A textbook of bacteriology, 8th ed. D.
Appleton-Century Company Inc, New York, NY.
9. Lipsitch M, Moxon ER. 1997. Virulence and transmissibility of pathogens:
what is the relationship? Trends Microbiol 5:31–37. https://doi.org/
10.1016/S0966-842X(97)81772-6.
10. Krause W, Matheis H, Wulf K. 1969. Fungaemia and funguria after oral
administration of Candida albicans. Lancet i:598–599.
11. Krause RM, Dimmock NJ, Morens DM. 1997. Summary of antibody
workshop: the role of humoral immunity in the treatment and preven-
tion of emerging and extant infectious diseases. J Infect Dis 176:
549–559.
12. Pirofski LA, Casadevall A. 2012. Q and A: what is a pathogen? A question
that begs the point. BMC Biol 10:6. https://doi.org/10.1186/1741-7007-
10-6.
13. Fortier AH, Slayter MV, Ziemia R, Meltzer MS, Nacy CA. 1991. Live
vaccine strain of Francisella tularensis: infection and immunity in mice.
Infec t Immun 59:2922–2928.
14. Lamanna C, Jones L. 1963. Lethality for mice of vegetative and spore
forms of Bacillus cereus and Bacillus cereus-like insect pathogens in-
jected intraperitoneally and subcutaneously. J Bacteriol 85:532–535.
15. Zhao WR, Wondoso, Hasi, Qin YX, Weng W, Lu SL. 1989. Selection of a
Brucella vaccine strain of low residual virulence by chemical mutagen-
esis. J Med Microbiol 30:143–148. https://doi.org/10.1099/00222615-30-
2-143.
16. Lee YH, Kasper LH. 2004. Immune responses of different mouse strains
after challenge with equivalent lethal doses of Toxoplasma gondii.
Parasite 11:89–97.
17. Kirkland TN, Fierer J. 1983. Inbred mouse strains differ in resistance to
lethal Coccidioides immitis infection. Infect Immun 40:912–916.
18. Berendt RF. 1978. Relationship of method of administration to respira-
tory virulence of Klebsiella pneumoniae for mice and squirrel monkeys.
Infec t Immun 20:581–583.
19. Yother J, Forman C, Gray BM, Briles DE. 1982. Protection of mice from
infection with *Streptococcus pneumoniae* by anti-phosphocholine anti-body. Infect Immun 36:184–188.

20. Anderson GW, Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander EP. 1996. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of *Yersinia pestis*. Infect Immun 64:4580–4585.

21. Clancy CJ, Nguyen MH, Alandoerffer R, Cheng S, Iczkowski K, Richardson M, Graybill JR. 2006. *Cryptococcus neoformans* var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152:2247–2255. https://doi.org/10.1099/mic.0.28798-0.

22. Oliver JD, Bockian R. 1995. In vivo resuscitation, and virulence towards mice, of viable but nonculturable cells of *Vibrio vulnificus*. Appl Environ Microbiol 61:2620–2623.

23. Shellam GR, Flexman JP. 1986. Genetically determined resistance to murine cytomegalovirus and herpes simplex virus in newborn mice. J Virol 58:152–156.

24. Rowley D. 1954. The virulence of strains of *Bacterium coli* for mice. Br J Exp Pathol 35:528–538.

25. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. 1982. Differences in virulence of clinical isolates of *Candida tropicalis* and *Candida albicans* in mice. Infect Immun 37:2233–2236.

26. Smith GR. 1972. Experimental aspergillosis in mice: aspects of resistance. J Hyg 70:741–754.

27. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 92:11490–11494.

28. Guida JD, Fejer G, Pirofski LA, Brosnan CF, Horwitz MS. 1995. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. J Virol 69:7674–7681.

29. Pinterest L, Malcolm GB, Plikaytis BD. 1990. *Listeria monocytogenes* intragastric and intraperitoneal approximate 50% lethal doses for mice are comparable, but death occurs earlier by intragastric feeding. Infect Immun 58:2940–2945.

30. Beam BL, Mastan S. 1977. Effect of cyclophosphamide on experimental *Nocardia asteroides* infection in mice. Infect Immun 16:995–1004.

31. Levenson VJ, Mallett CP, Hale TL. 1995. Protection against local *Shigella sonnei* infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect Immun 63:2762–2765.

32. Haggerty RM, John DT. 1978. Innate resistance of mice to experimental infection with *Naegleria fowleri*. Infect Immun 20:73–77.

33. Molnár C, Hervésy Z, Rozgonyi F, Gemmell CG. 1994. Pathogenicity and virulence of coagulase negative *Staphylococcus* in relation to adherence, hydrophobicity, and toxin production in vitro. J Clin Pathol 47:743–748.

34. Finke M, Duchêne M, Eckhardt A, Domdey H, von Specht BU. 1990. Protection against experimental *Pseudomonas aeruginosa* infection by recombinant P aeruginosa *lipoprotein I* expressed in *Escherichia coli*. Infect Immun 58:2241–2244.

35. Yoshida S, Mizuguchi Y. 1986. Multiplication of *Legionella pneumophila* Philadelphia-1 in cultured peritoneal macrophages and its correlation to susceptibility of animals. Can J Microbiol 32:438–442.

36. Smith IM, Wilson AP, Hazard EC, Hummer WK, Dewey ME. 1960. Death from staphylococci in mice. Infect Dis 103:369–378.

37. Mojgani N, Maldjae V, Rahbar M, Mirafzali SM, Khoshnood S, Hatami A. 2013. Intraperitoneal inoculation of *Haemophilus influenzae* local isolates in BALB/c mouse model in the presence and absence of virulence enhancement agents. Indian J Med Microbiol 31:148–153. https://doi.org/10.4103/0255-0857.115236.

38. Singh KV, Qin X, Weinstock GM, Murray BE. 1998. Generation and testing of mutants of *Enterococcus faecalis* in a mouse peritonitis model. J Infect Dis 178:1416–1420.

39. Cheers C, McKenzie IF. 1978. Resistance and susceptibility of mice to bacterial infection: genetics of listeriosis. Infect Immun 19:755–762.

40. Welkos SL, Keener TJ, Gibbs PH. 1986. Differences in susceptibility of inbred mice to *Bacillus anthracis*. Infect Immun 51:795–800.

41. Parker JC, Whitman MD, Richter CB. 1978. Susceptibility of inbred and outbred mouse strains to *Sendai* virus and prevalence of infection in laboratory rodents. Infect Immun 19:123–130.